Skip Ribbon Commands
Skip to main content

Clin Asst Prof Ang Mei-Kim

Clin Asst Prof Ang Mei-Kim


Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Head & Neck, Thoracic-Oncology

Conditions Treated by this Doctor:
Head and Neck Cancer, Lung Cancer, Thoracic Cancers.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Asst Professor at Duke-NUS Medical School


Dr Ang Mei-Kim is a Senior Consultant working at the Division of Medical Oncology at the National Cancer Centre Singapore. Her research interests are primarily in head and neck squamous cell carcinoma, in particular, the development of predictive and prognostic markers, database development as well as clinical trial development in this area. Her clinical interests are in the treatment of patients with head and neck cancers as well as thoracic malignancies.


  • BA 
  • MRCP (UK)

Professional Appointments and Committee Memberships

  • Clinical Tutor, NUS Yong Loo Lin School of Medicine
  • Clinical Assistant Professor, Duke-NUS Medical School
  • Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore 
  • Visiting Consultant, Khoo Teck Puat Hospital Singapore 
  • Medical Protection Society, Member 
  • American Society of Clinical Oncology, Member 
  • Singapore Society of Oncology, Member


  • SingHealth RISE awards, Outstanding Faculty Award, 2015 
  • SingHealth Publish! Award, SingHealth award, 2012 
  • Silver Award, Singapore Health Quality Service Award, 2010 
  • Best Poster Award, Singapore General Hospital Annual Scientific Meeting 2008 
  • Singapore Millennium Foundation, 2007 
  • Scholarship Award for Associate Investigators: Immunohistochemical analysis and gene expression profiling in peripheral T-cell lymphomas, Scholarship Award 2009 
  • Best Poster Award, European Society of Medical Oncology Conference Lugano (ECLU) 2007 
  • SingHealth Registrar Service Award, 2007 
  • Lewin Prize in Surgery, University of Cambridge Medical School, UK, 2000

Research Interests

  • Prognostic markers in Head and neck squamous cell carcinoma
  • Development of clinical trials in head and neck squamous cell carcinoma
  • Clinical trials in lung cancer


  • Marvalim C, Wong JX, Sutiman N, Lim WT, Tan SW, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Tan EH, Chowbay B. Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. Pharmacogenet Genomics. 2017 Mar;27(3):120-123. PMID: 28059867 
  • Rajasekaran T, Ng QS, Tan DS, Lim WT, Ang MK, Toh CK, Chowbay B, Kanesvaran R, Tan EH. Metronomic chemotherapy: A relook at its basis and rationale. Cancer Lett. 2017 Mar 1;388:328-333. doi: 10.1016/j.canlet.2016.12.013. Epub 2016 Dec 18. PMID: 28003122 
  • Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2016 Nov 28. pii: S1556-0864(16)33533-X. doi: 10.1016/j.jtho.2016.11.2225. [Epub ahead of print] PMID: 27908825 
  • Chan WY, Ang MK, Tan DS, Koh WL, Kwek JW. Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report. Radiol Case Rep. 2016 May 18;11(3):245-7. doi: 10.1016/j.radcr.2016.04.010. PMID: 27594959 
  • Tay GC, Iyer NG, Ong WS, Tai D, Ang MK, Ha TC, Soo KC, Tan HK. Outcomes and Prognostic Factors of Radiation-Induced and De Novo Head and Neck Squamous Cell Carcinomas. Otolaryngol Head Neck Surg. 2016 May;154(5):880-7. doi: 10.1177/0194599816631726. PMID: 26956200 
  • Ang SH, Haaland B, Acharyya S, Thu MM, Krisna SS, Hwang SG, Tan PH, Ng QS, Tan DS, Tai WM, Tan EH, Lim WT, Ang MK (2014). Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. Head Neck: Epub ahead of print. Nov 2015 PMID: 24953865 
  • Tan EH, Tan DS, Li WY, Haaland B, Ang MK, Chau NM, Toh CK, Tan IB, Koh TS, Thng CH, Chowbay B, Hui KM, Lim WT, Ng QS (2015) Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer . Lung Cancer Jun 2015 88(3) : 289-96 PMID: 25896396 (Impact Factor: 3.958) 
  • Iyer NG, Tan DSW, Tan VK, Wang W, Hwang J, Tan N-C, Sivanandan R, Tan H-K., Lim WT, Ang M-K, Wee J, Soo K-C and Tan EH. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121:1599-1607. Epub 2015 Jun 4 PMID: 26383792 (Impact Factor: 5.068) 
  • Jain A, Lim C, Gan EM, Ng DZ, Ng QS, Ang MK, Takano A, Chan KS, Tan WM, Kanesvaran R, Toh CK, Loo CM, Hsu AA, Devanand A, Lim CH, Koong HN, Koh TP, Fong KW, Yap SP, Kim SW, Chowbay B, Oon L, Lim KH, Lim WT, Tan EH, Tan DS (2015) Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE May 2015 10(5) : e0123587 PMID: 25955322 (Impact Factor: 3.234) 
  • Tan TW, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, Ng QS, Tan DS, Ong WS, Tan SH, Yip CS, Quah D, Soo KC, Wee J (2015) Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma . Int J Radiat Oncol Biol Phys Apr 2015 91(5) : 952-60 PMID: 25832687 (Impact Factor: 4.176)

Research Trials

  • A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients, 2014 
  • A phase II, multicenter, three-cohort of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/ metastatic disease, 2003